FLT3 expression initiates in fully multipotent mouse hematopoietic progenitor cells

被引:57
|
作者
Buza-Vidas, Natalija [1 ]
Woll, Petter [1 ]
Hultquist, Anne [2 ]
Duarte, Sara [1 ]
Lutteropp, Michael [1 ]
Bouriez-Jones, Tiphaine [1 ]
Ferry, Helen [1 ]
Luc, Sidinh [1 ,2 ]
Jacobsen, Sten Eirik Waelgaard [1 ,3 ]
机构
[1] Univ Oxford, John Radcliffe Hosp, Weatherall Inst Mol Med, Haematopoiet Stem Cell Lab, Oxford OX3 9DS, England
[2] Lund Univ, Lund Stem Cell Ctr, Hematopoiet Stem Cell Lab, Lund, Sweden
[3] Univ Oxford, John Radcliffe Hosp, Weatherall Inst Mol Med, MRC,Mol Haematol Unit, Oxford OX3 9DS, England
基金
英国医学研究理事会;
关键词
STEM-CELLS; LINEAGE COMMITMENT; DIFFERENTIATION; IDENTIFICATION; SURVIVAL; LEUKEMIA; LIGAND; MODEL; STAGE; MARKS;
D O I
10.1182/blood-2010-10-316232
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Lymphoid-primed multipotent progenitors with down-regulated megakaryocyte-erythroid (MkE) potential are restricted to cells with high levels of cell-surface FLT3 expression, whereas HSCs and MkE progenitors lack detectable cell-surface FLT3. These findings are compatible with FLT3 cell-surface expression not being detectable in the fully multipotent stem/progenitor cell compartment in mice. If so, this process could be distinct from human hematopoiesis, in which FLT3 already is expressed in multipotent stem/progenitor cells. The expression pattern of Flt3 (mRNA) and FLT3 (protein) in multipotent progenitors is of considerable relevance for mouse models in which prognostically important Flt3 mutations are expressed under control of the endogenous mouse Flt3 promoter. Herein, we demonstrate that mouse Flt3 expression initiates in fully multipotent progenitors because in addition to lymphoid and granulocyte-monocyte progenitors, FLT3(-) Mk- and E-restricted downstream progenitors are also highly labeled when Flt3-Cre fate mapping is applied. (Blood. 2011;118(6):1544-1548)
引用
收藏
页码:1544 / 1548
页数:5
相关论文
共 50 条
  • [1] Loss of flk-2/flt3 expression during commitment of multipotent mouse hematopoietic progenitor cells to the mast cell lineage
    Pharr, PN
    Hofbauer, A
    EXPERIMENTAL HEMATOLOGY, 1997, 25 (07) : 620 - 628
  • [2] Effect of FLT3 inhibition on normal hematopoietic progenitor cells
    Weisel, Katja C.
    Yildirim, Sedat
    Schweikle, Eric
    Kanz, Lothar
    Moehle, Robert
    HEMATOPOIETIC STEM CELLS VI, 2007, 1106 : 190 - 196
  • [3] Regulation of FLT3 and its ligand in normal hematopoietic progenitor cells
    Weisel, Katja C.
    Yildirim, Sedat
    Schweikle, Eric
    Kanz, Lothar
    Moehle, Robert
    ANNALS OF HEMATOLOGY, 2009, 88 (03) : 203 - 211
  • [4] Regulation of FLT3 and its ligand in normal hematopoietic progenitor cells
    Katja C. Weisel
    Sedat Yildirim
    Eric Schweikle
    Lothar Kanz
    Robert Möhle
    Annals of Hematology, 2009, 88 : 203 - 211
  • [5] Simultaneous activation of B lymphocyte and macrophage differentiation characteristics in mouse multipotent progenitor cells by FLT3 ligand.
    Dannaeus, K
    Nilsson, K
    Jonsson, JI
    EXPERIMENTAL HEMATOLOGY, 1998, 26 (08) : 694 - 694
  • [6] EXPRESSION OF THE FLT3 RECEPTOR AND ITS LIGAND ON HEMATOPOIETIC-CELLS
    BRASEL, K
    ESCOBAR, S
    ANDERBERG, R
    DEVRIES, P
    GRUSS, HJ
    LYMAN, SD
    LEUKEMIA, 1995, 9 (07) : 1212 - 1218
  • [7] Selective Expression of Flt3 within the Mouse Hematopoietic Stem Cell Compartment
    Mooney, Ciaran James
    Cunningham, Alan
    Tsapogas, Panagiotis
    Toellner, Kai-Michael
    Brown, Geoffrey
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2017, 18 (05)
  • [8] Effects of dexamethasone on Flt3 receptor expression and proliferation induced by recombinant human Flt3 ligand in malignant hematopoietic cells
    Xu, ZX
    Xu, Y
    Zhu, JK
    Li, CX
    Li, Y
    Zhang, XG
    ACTA PHARMACOLOGICA SINICA, 2001, 22 (06) : 534 - 540
  • [9] Expression of FLT3 receptor and response to FLT3 ligand by leukemic cells
    Drexler, HG
    LEUKEMIA, 1996, 10 (04) : 588 - 599
  • [10] THE EXPRESSION OF FMS, KIT AND FLT3 IN HEMATOPOIETIC MALIGNANCIES
    BIRG, F
    ROSNET, O
    CARBUCCIA, N
    BIRNBAUM, D
    LEUKEMIA & LYMPHOMA, 1994, 13 (3-4) : 223 - 227